Brief Summary
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination.
Participants will:
* Receive the standard or new drug combination after transplant
* Visit the doctor’s office for check-ups and tests after transplant that are routine for most transplant patients
* Take surveys about physical and emotional well-being
* Give blood and stool samples.
Protocol Interventions
Drug: Conditioning Regimen A, Drug: Conditioning Regimen B, Drug: Conditioning Regimen C, Drug: Conditioning Regimen D, Drug: Conditioning Regimen E, Procedure: Hematopoietic Cell Transplantation, Drug: PTCy (25 mg/kg D3, D4), Drug: Post-transplant Tacrolimus, Drug: Post-transplant Mycophenolate mofetil, Drug: Post-transplant Ruxolitinib, Drug: Supportive Care: Growth Factors, Procedure: Supportive Care: Blood Products, Other: Supportive Care: Infection Prophylaxis, Other: Supportive Care: Intravenous immune globulin (IVIG), Drug: Supportive Care: Seizure prophylaxis, Other: Supportive Care: Monitoring and management of CRS, Drug: Supportive Care: Prophylaxis against infections, Other: Supportive Care: Lipid elevations, Other: Study treatment compliance, Other: Prohibited Concomitant Therapy, Other: Permitted Concomitant Therapy